

Decision number: TPE-D-2114291967-28-01/F

Helsinki, 25 February 2015

DECISION ON TESTING PROPOSAL(S) SET OUT IN A REGISTRATION PURSUANT TO ARTICLE 40(3) OF REGULATION (EC) NO 1907/2006

For dimethy registration	-	DOCUMENTOWN REPORTS AND ADDRESS OF THE PARTY	-dicarbox	ylate, CA	S No 9	94-60-0	(EC No	202-347	7-5),
Addressee:					1				

The European Chemicals Agency (ECHA) has taken the following decision in accordance with the procedure set out in Articles 50 and 51 of Regulation (EC) No 1907/2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH Regulation).

I. Procedure

Pursuant to Article 40(1) of the REACH Regulation, ECHA has examined the following testing proposal submitted as part of the registration dossier in accordance with Articles 10(a)(ix) and 12(1)(d) thereof for dimethyl cyclohexane-1,4-dicarboxylate, CAS No 94-60-0 (EC No 202-347-5), submitted by (Registrant).

- Prenatal Developmental Toxicity Study according to OECD Guideline 414

This decision is based on the registration dossier as submitted with submission number, for the tonnage band of 100 to 1000 tonnes per year. This decision does not take into account any updates after 30 October 2014, the date upon which ECHA notified its draft decision to the Competent Authorities of the Member States pursuant to Article 51(1) of the REACH Regulation.

This decision does not imply that the information provided by the Registrant in his registration dossier is in compliance with the REACH requirements. The decision does not prevent ECHA from initiating a compliance check on the registration at a later stage.

ECHA received the updated registration dossier containing the above-mentioned testing proposal for further examination pursuant to Article 40(1) on 9 December 2013.

ECHA held a third party consultation for the testing proposal from 15 April 2014 until 30 May 2014. ECHA received information from third parties (see section III below).

On 22 August 2014 ECHA sent the draft decision to the Registrant and invited him to provide comments within 30 days of the receipt of the draft decision.

By 29 September 2014 the Registrant did not provide any comments on the draft decision to ECHA.

On 30 October 2014 ECHA notified the Competent Authorities of the Member States of its draft decision and invited them pursuant to Article 51(1) of the REACH Regulation to submit proposals for amendment of the draft decision within 30 days of the receipt of the notification.



As no proposal for amendment was submitted, ECHA took the decision pursuant to Article 51(3) of the REACH Regulation.

II. Testing required

A. Tests required pursuant to Article 40(3)

The Registrant shall carry out the following proposed test pursuant to Article 40(3)(a) and 13(4) of the REACH Regulation using the indicated test method and the registered substance subject to the present decision:

- Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.; test method: EU B.31/OECD 414) in rats or rabbits, oral route.

B. Deadline for submitting the required information

Pursuant to Articles 40(4) and 22(2) of the REACH Regulation, the Registrant shall submit to ECHA by **3 March 2016** an update of the registration dossier containing the information required by this decision, including, where relevant, an update of the Chemical Safety Report.

Note for consideration by the Registrant:

The Registrant may adapt the testing requested above according to the specific rules outlined in Annexes VI to X and/or according to the general rules contained in Annex XI of the REACH Regulation. In order to ensure compliance with the respective information requirement, any such adaptation will need to have a scientific justification, referring to and conforming with the appropriate rules in the respective Annex, and an adequate and reliable documentation.

Failure to comply with the request(s) in this decision, or to fulfil otherwise the information requirement(s) with a valid and documented adaptation, will result in a notification to the Enforcement Authorities of the Member States.

III. Statement of reasons

The decision of ECHA is based on the examination of the testing proposal submitted by the Registrant for the registered substance and scientific information submitted by third parties.

A. Tests required pursuant to Article 40(3)

Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.)

A pre-natal developmental toxicity study for a first species is a standard information requirement as laid down in Annex IX, Section 8.7.2. of the REACH Regulation. The information on this endpoint is not available for the registered substance but needs to be present in the technical dossier to meet the information requirements. Consequently there is an information gap and it is necessary to provide information for this endpoint.

The Registrant has submitted a testing proposal for a pre-natal developmental toxicity study according to EU B.31/OECD 414.

CONFIDENTIAL 3 (4)



ECHA considers that the proposed study is appropriate to fulfil the information requirement of Annex IX, Section 8.7.2. of the REACH Regulation.

The Registrant did not specify the route nor the species to be used for testing. According to the test method EU B.31/OECD 414, the rat is the preferred rodent species, the rabbit the preferred non-rodent species and the test substance is usually administered orally. ECHA considers these default parameters appropriate and testing should be performed by the oral route with the rat or the rabbit as a first species to be used.

b) Consideration of the information received during third party consultation

ECHA received information concerning the testing proposal during the third party consultation.

Third party information 1:

A third party has proposed that "[a]s the dossier of cyclohexane-1,4-dicarboxylic acid shows a testing proposal of a prenatal developmental toxicity study, the registrant could specify a read-across approach also for this endpoint."

ECHA acknowledges that the third party has proposed a read across approach for the Registrant to consider.

ECHA notes that it is the Registrant's responsibility to consider and justify any adaptation of the information requirements in accordance with the relevant conditions as established in Annex XI, Section 1.5. Therefore, the Registrant should assess whether he can justify a read-across as suggested by the third party. If the adaptation can be justified, he should include the adaptation argument with all necessary documentation in the registration dossier. Such update can only be taken into consideration in the decision-making if it is submitted before the draft decision is sent to the Member State Competent Authorities pursuant to Article 51(1) of the REACH Regulation.

ECHA notes that the information provided by the third party is currently insufficient for demonstrating that the conditions of Annex XI, Section 1.5. of the REACH Regulation are met. For example, it is not explained why the structural dissimilarities would result in similar toxicological properties for the hazard endpoint pre-natal developmental toxicity. Furthermore, ECHA notes that the proposed read-across is based on a study which is proposed to be performed for the source substance and the results are therefore not available. Therefore, ECHA cannot conclude on the adequacy of the study. Therefore, the information provided by the third party would not be sufficient to adapt the standard information requirement.

Third party information 2:

A third party has provided information on an OECD 421 screening study performed with the registered substance subject to the present decision.

However, ECHA notes that an OECD 421 screening study is not a test method that corresponds to the standard information requirement of Annex IX, Section 8.7.2 for a prenatal developmental toxicity study because it does not provide equivalent information. The screening study does not cover adequate and reliable the key parameters of a pre-natal developmental toxicity study which are, for example, examinations of the foetuses for skeletal and visceral malformations. Therefore, the criteria listed in Annex XI, Section 1.1.2. are not met.



c) Outcome

Therefore, pursuant to Article 40(3)(a) of the REACH Regulation, the Registrant is requested to carry out the proposed study with the registered substance subject to the present decision: Pre-natal developmental toxicity study in rats or rabbits, oral route (test method: EU B.31/OECD 414).

IV. Adequate identification of the composition of the tested material

The process of examination of testing proposals set out in Article 40 of the REACH Regulation aims at ensuring that the new study meets real information needs. Within this context, the Registrant's dossier was sufficient to confirm the identity of the substance to the extent necessary for examination of the testing proposal. The Registrant must note, however, that this information has not been checked for compliance with the substance identity requirements set out in Section 2 of Annex VI of the REACH Regulation.

In addition, it is important to ensure that the particular sample of substance tested in the new study is appropriate to assess the properties of the registered substance, taking into account any variation in the composition of the technical grade of the substance as actually manufactured. If the registration of the substance covers different grades, the sample used for the new study must be suitable to assess these.

Finally, there must be adequate information on substance identity for the sample tested and the grade(s) registered to enable the relevance of the study to be assessed.

V. Information on right to appeal

An appeal may be brought against this decision to the Board of Appeal of ECHA under Article 51(8) of the REACH Regulation. Such appeal shall be lodged within three months of receiving notification of this decision. Further information on the appeal procedure can be found on the ECHA's internet page at http://www.echa.europa.eu/regulations/appeals. The notice of appeal will be deemed to be filed only when the appeal fee has been paid.



Leena Ylä-Mononen Director of Evaluation